Replies to post #85976 on PharmaCyte Biotech Inc (PMCB)

[thenewmixer]

well Ciab what is it when kw states we are three three.......and we will name a cross in 30 days......that was 2 months ago.......looks like a lie.....but you have been fooled many times

[concordia]

Well was this a lie?

10 APR 14
Nuvilex Engages ViruSure to Establish Cell Banks for Phase 2b Clinical Trials in Pancreatic Cancer

Or this?
27 MAR 15

today announced that the genetically modified cells that are required for its three planned clinical trials have been fully tested and are in the process of being propagated to produce all of the cells necessary for the clinical trials.
Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte Biotech, stated, “We are very pleased that work being done to grow the cells required for our clinical trials has proceeded according to our plans. Together with our partner, Austrianova, we are complying with all current regulatory guidelines to ensure that these cells will be made available to us as quickly as possible so we can commence our clinical trials in a timely fashion.”

How about this?
19 MAY 15

Q: What other milestones do you hope to accomplish in 2015?

Initiation of the Phase 2b clinical trial in Australia in patients with advanced pancreatic cancer. This is expected to begin in late 3Q2015.

2. Initiation of the Phase 1/2 clinical trial on the effectiveness of PharmaCyte’s pancreatic cancer treatment dealing with pain associated with advanced pancreatic cancer. This trial, to be conducted in the U.S., is expected to begin in late 3Q2015.

3. Initiation of the Phase 1/2 clinical trial on the effectiveness of PharmaCyte’s pancreatic cancer treatment in slowing the accumulation of malignant ascites fluid. This trial, to also be conducted in the U.S., is expected to occur in late 3Q2015 or early 4Q2015.

Maybe this?

04 JAN 16

2016 Milestones as Its Pancreatic Cancer Treatment Moves Into a Clinical Trial

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 arrive as this is the year that we will get into the clinic with our pancreatic cancer treatment. Our shareholders should understand that nothing whatsoever will deter our efforts to get into the clinic and to showcase our novel treatment for pancreatic cancer.”

An Investigational New Drug Application (IND) will be filed with the FDA following a pre-IND meeting with the FDA.

PharmaCyte’s clinical trial in pancreatic cancer will get underway with Translational Drug Development (TD2) coordinating the trial globally and conducting it in the United States. Clinical Network Services (CNS) will conduct the trial in Europe and Australia in alliance with TD2.

PharmaCyte will hold an annual shareholder meeting.